Abstract:Objective To assess the clinical efficacy and safety of intravenous recombinant tissue plasminogen activator (rtPA) in the treatment of acute ischemic stroke and to investigate the thrombolytic time window and the related factors affecting the prognosis of thrombolysis. Methods Ninety-four patients with acute ischemic stroke (40 patients in the rtPA group, 54 patients in the control group) were analyzed retrospectively. The National Institute of Health Stroke Scale (NIHSS) was used to assess neurological function at 24 hours after onset. Early neurological improvement was defined as NIHSS improvement ≥4 or the neurological function recovered completely 24 hours after admissioa The patients were assessed by the modified Rankin Scale (mRS), and the clinical efficacy was assessed by the Barthel Index (BI) and MHSS. Good outcome was defined as BI≥95, mRS ≤1 or NIHSS≤1. In addition, the incidence and mortality of the symptomatic intracranial hemorrhage (sICH) were assessed Results The rate of early neurological improvement at 24 hours in the rtPA group was significantly higher than that in the control group (37.5% vs. 13.0%,OR = 3.900; P =0.007). The rate of good outcome at day 14 after admission in the rtPA group was significantly higher than that in the control group (OR =2.654,95% CI 1.089-7.235, P=0.035). The incidence of sICH in the rtPA group during the hospitali2ation was significantly higher than that in the control group (15.00% vs. 1. 85%, P =0.033), however, there was no significant difference in mortality (17.50% vs. 9. 36%, P =0.054). The multivariate regression analysis indicated that the serum glucose≥8 mmol/L, basilar artery occlusion, NIHSS score≥20, and an early sign of infarction on CT were the independent predicting factors for poor outcome; the rate of good outcome of intravenous thrombolysis within 3 h was significantly higher than that in the 4.5 to 6 h thrombolytic group (47.1% vs. 16.7%, P = 0.034). Conclusions Thrombolysis treatment with intravenous rtPA within 6 h after the onset was safe and effective for patients with acute ischemic stroke, in which the efficacy of intravenous thrombolysis was better within 3 h. The serum glucose≥8 mmol/L, basilar artery occlusion, NIHSS score≥20, and an early sign of infarction on CT were the independent predicting factors for poor outcome.

Intraclot Recombinant Tissue-type Plasminogen Activator Reduces Perihematomal Edema and Mortality in Patients with Spontaneous Intracerebral Hemorrhage

Preliminary Study of Minimally Invasive Intracranial Hematoma Evacuation Surgery Combined with rt-PA in Patients with Spontaneous Intracerebral Hemorrhage

Iodinated Contrast Agents Reduce the Efficacy of Intravenous Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients: A Multicenter Cohort Study

Study of intravenous thrombolysis with recombinant tissue plasminogen activator(rtPA)in isolatedpenetrating artery territory infarcts

Alteplase vs. urokinase treatment after minimally invasive surgery for spontaneous intracerebral hemorrhage: a single-center experience

No exacerbation of perihematomal edema with intraclot urokinase in patients with spontaneous intracerebral hemorrhage

Abstract TMP81: Effect of Post Thrombolytic Intracerebral Hemorrhage Volume on 90-day Outcomes in Acute Ischemic Stroke Patients

Intra-Arterial Local Thrombolysis for Hyperacute Cerebral Infarction with Recombinant Tissue Plasminogen Activato

Efficacy of Thrombolysis by Intravenous Recombinant Tissue Plasminogen Activator in Hyperacute Cerebral Infarction

Therapeutic Effect of Recombinant Tissue Plasminogen Activator on Acute Cerebral Infarction at Different Times.

Non-atrial Fibrillation Was Associated with Early Neurological Improvement after Intravenous Thrombolysis with Rt-Pa in Patients with Acute Ischemic Stroke

Effect of post thrombolytic intracerebral hemorrhage volume on 90-day outcomes in acute ischemic stroke patients

Effects of Early Intensive Blood Pressure Lowering on Early Reperfusion and Outcome after Intravenous Thrombolysis in Patients with Acute Ischemic Stroke

Minimally Invasive Stereotactic Puncture and Thrombolysis Therapy Improves Long-Term Outcome after Acute Intracerebral Hemorrhage

Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke-a Single Center Retrospective Study

Intravenous Thrombolytic Therapy among 25 Patients with Acute Ischemic Stroke

Intraventricular Recombinant Tissue Plasminogen Activator in Treatment of Aneurysmal Intraventricular Hemorrhage: A Meta-Analysis.

Postoperative Rehemorrhage of Minimally Invasive Hematoma Aspiration：Etiological Analysis

Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis

Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism

Evaluation of efficacy and safety of Reteplase and Alteplase in the treatment of hyper-acute cerebral infarction.